For research use only. Not for therapeutic Use.
MDK6620（Cat No.:I031750）, also referred to as BTYNB IMP1 Inhibitor is a compound that acts as an inhibitor of the oncofetal mRNA-binding protein IMP1. It displays an inhibitory effect on the binding of IMP1 to c-Myc mRNA, with an IC50 value of 5 μM. By targeting IMP1, MDK6620 potentially disrupts the interaction between IMP1 and c-Myc mRNA, which may have implications in cancer-related processes. Further research is necessary to explore the therapeutic potential of MDK6620 in cancer treatment and its impact on IMP1-mediated functions.
| Catalog Number | I031750 |
| CAS Number | 304456-62-0 |
| Synonyms | BTYNB IMP1 Inhibitor; MDK6620; MDK-6620; MDK 6620. |
| Molecular Formula | C12H9BrN2OS |
| Purity | 98% |
| Target | c-Myc |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | 4°C, protect from light |
| IUPAC Name | 2-[[(5-bromo-2-thienyl)methylene]amino]-benzamide |
| InChI | InChI=1S/C12H9BrN2OS/c13-11-6-5-8(17-11)7-15-10-4-2-1-3-9(10)12(14)16/h1-7H,(H2,14,16)/b15-7+ |
| InChIKey | OZEADOPONHLEDS-VIZOYTHASA-N |
| SMILES | O=C(N)C1=CC=CC=C1/N=C/C2=CC=C(Br)S2 |
| Reference | 1. L. Mahapatra, N. Andruska, C. Mao, et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl. Oncol. 10(5), 818-827 (2017). |
